Cooper Companies Shares Drop 21% After Q3 Revenue Miss

Cooper Companies shares fell 21.2% following a third-quarter revenue miss and cautious near-term guidance. This occurred even as the medical device manufacturer beat earnings expectations and finalized its decision to retain its surgical division.

The company reported Q3 2026 revenue of $1.07 billion, which fell short of the $1.1 billion analyst consensus. Despite the top-line miss, non-GAAP earnings reached $1.15 per share, exceeding the $1.12 estimate.

"We're now positioned to enter fiscal 2027 with a healthier channel and stronger foundation," said Al White, CEO of Cooper Companies, in a statement regarding the results.

Market Reaction and Operational Context

The stock's decline occurred in two stages. It saw a 6.22% drop during regular trading, followed by a 16.04% slide in after-hours sessions. Management attributed the revenue shortfall to a deliberate decision to reduce channel inventory. This strategy was intended to stabilize supply chains, rather than representing a reflection of weakened end-market demand.

"We don't have a manufacturing issue. Our team is strong," White added during the earnings call.

Strategic Review of CooperSurgical

Beyond the quarterly financial results, the board concluded its strategic review of the CooperSurgical business. After evaluating potential interest from external parties, the board determined that the offers received did not adequately reflect the unit's intrinsic value. Consequently, the company will retain the division. It will continue its integration within the broader portfolio instead of pursuing a divestiture.

Financial Implications

For investors, the primary concern remains the balance between short-term inventory management and long-term growth. By clearing channel inventory, the firm aims to reduce pressure on future quarters, though the market reacted negatively to the immediate revenue impact. The decision to keep CooperSurgical signals a commitment to the unit's current growth trajectory. This effectively ends speculation that the company would seek to unlock capital through a sale of its surgical assets.